2-[2-(2-Nitrosoethoxy)ethoxy]ethanol

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-[2-(2-Nitrosoethoxy)ethoxy]ethanol
• 英文别名: 2-[2-(2-nitrosoethoxy)ethoxy]ethanol
• 化学式: C₆H₁₃NO₄
• 分子量: 163.17
• InChiKey: DRHBYSFQIWOMPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  11
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  68.1
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• NANOTUBE DISPERSANTS AND DISPERSANT FREE NANOTUBE FILMS THEREFROM
  申请人：Walczak Ryan M.

  公开号：US20140083752A1

  公开（公告）日：2014-03-27

  A degradable polymeric nanotube (NT) dispersant comprises a multiplicity of NT associative groups that are connected to a polymer backbone by a linking group where there are cleavable groups within the polymer backbone and/or the linking groups such that on a directed change of conditions, bond breaking of the cleavable groups results in residues from the degradable polymeric NT dispersant in a manner where the associative groups are uncoupled from other associative groups, rendering the associative groups monomelic in nature. The degradable polymeric nanotube (NT) dispersant can be combined with carbon NTs to form a NT dispersion that can be deposited to form a NT film, or other structure, by air brushing, electrostatic spraying, ultrasonic spraying, ink-jet printing, roll-to-roll coating, or dip coating. The deposition can render a NT film that is of a uniform thickness or is patterned with various thicknesses. Upon deposition of the film, the degradable polymeric nanotube (NT) dispersant can be cleaved and the cleavage residues removed from the film to yield a film where contact between NTs is unencumbered by dispersants, resulting in highly conductive NT films.

  可降解聚合物纳米管（NT）分散剂包括多个NT关联基团，这些基团通过连接基团连接到聚合物骨架，其中聚合物骨架和/或连接基团中有可断裂的基团，因此在指定条件的变化下，可断裂基团的键断裂会导致可降解聚合物NT分散剂的残留物以一种方式分散，其中关联基团与其他关联基团解耦，使关联基团具有单体性质。可降解聚合物纳米管（NT）分散剂可以与碳NT结合形成NT分散液，可以通过喷雾、静电喷涂、超声波喷涂、喷墨印刷、卷对卷涂覆或浸涂沉积形成NT薄膜或其他结构。沉积可以使NT薄膜具有均匀的厚度或具有不同厚度的图案。在薄膜沉积后，可降解聚合物纳米管（NT）分散剂可以被断裂并从薄膜中移除，以产生接触NT的膜，该膜不受分散剂的阻碍，从而产生高导电性NT薄膜。
• USE OF INHIBITORS OF TOLL-LIKE RECEPTORS IN THE PREVENTION AND TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA AND DISEASES RELATED THERETO
  申请人：Idera Pharmaceuticals, Inc.

  公开号：EP3087988A2

  公开（公告）日：2016-11-02

  The invention provides the use of TLR inhibitors or a pharmaceutically acceptable derivative thereof, optionally in combination with one or more lipid lowering composition, cholesterol lowering composition, diuretics, non-steroidal anti-inflammatory compounds (NSAIDs), antibodies, antisense oligonucleotides, TLR agonists, TLR antagonists, peptides, proteins or gene therapy vectors or combinations thereof for the prevention or treatment of hypercholesterolemia and/or hyperlipidemia and/or diseases associated therewith.

  本发明提供了TLR抑制剂或其药学上可接受的衍生物，可选择与一种或多种降脂组合物、降胆固醇组合物、利尿剂、非甾体抗炎化合物（NSAIDs）、抗体、反义寡核苷酸、TLR激动剂、TLR拮抗剂、肽、蛋白质或基因治疗载体或其组合结合使用，用于预防或治疗高胆固醇血症和/或高脂血症和/或与之相关的疾病。
• COMPOSITIONS FOR INHIBITING GENE EXPRESSION AND USES THEREOF
  申请人：Idera Pharmaceuticals, Inc.

  公开号：EP3272870A1

  公开（公告）日：2018-01-24

  The inventors have examined the means for providing more efficacious gene expression blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of gene expression blocking molecules. These features include the presence of multiple 3' ends and a linker at the 5' ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technologies.

  本发明者研究了提供更有效基因表达阻断化合物的方法。本发明者发现了新的结构特征，这些特征令人惊讶地提高了基因表达阻断分子的功效。这些特征包括多个 3'末端和 5'末端的连接体。令人惊讶的是，这些特征以降低化合物生物不稳定性的方式提高了基因表达阻断化合物的功效。更令人惊讶的是，这种效果已被发现适用于 DNA 和 RNA 寡核苷酸化合物，并可应用于传统的反义和 RNAi 技术。
• MULTI-ARM POLYMERIC TARGETING ANTI-CANCER CONJUGATE
  申请人：Bright Gene Bio-Medical Technology Co., Ltd.

  公开号：EP3459546A1

  公开（公告）日：2019-03-27

  Disclosed is a multi-arm targeting drug conjugate modified by a water-soluble polymer; the drug conjugate has the structural formula of (III). In formula (III), R is an organic core, POLY is a polymer, L is a multivalent linker, T is a targeting molecule, D is a camptothecin-based drug, and q is any integer between 3 and 8. The drug conjugate may improve the poor water solubility, high toxicity and low bioavailability of camptothecin-based drugs.

  本发明公开了一种由水溶性聚合物修饰的多臂靶向药物共轭物；该药物共轭物的结构式为(III)。式（III）中，R 是有机核，POLY 是聚合物，L 是多价连接体，T 是靶向分子，D 是喜树碱类药物，q 是 3 到 8 之间的任意整数。该药物共轭物可改善喜树碱类药物水溶性差、毒性大和生物利用率低的问题。
• Synthesis of small molecule histone deacetylase 6 degraders, compounds formed thereby, and pharmaceutical compositions containing them
  申请人：Wisconsin Alumni Research Foundation

  公开号：US11045458B2

  公开（公告）日：2021-06-29

  Histone deacetylase (“HDAC”)-selective inhibitors covalently bonded to a linker covalently bonded to an E3 ubiquitin ligase ligand, and salts thereof; pharmaceutical compositions containing them; methods of using the composition to inhibit neoplastic cell growth in mammals, including humans.

  组蛋白去乙酰化酶（"HDAC"）选择性抑制剂，共价键合到与 E3 泛素配体共价键合的连接体上，及其盐类；含有它们的药物组合物；使用该组合物抑制哺乳动物（包括人类）肿瘤细胞生长的方法。